Issues related to Medicare Part D and Medicare Part B reimbursement and coverage. Issues related to drug pricing. Issues related to biosimilar regulation. Issues related to 340B reform.
Source-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 19, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- OGR
- Client
- AMGEN USA INC
- Filing UUID
- acb71b6a-01c7-42b2-bbee-a9b3f924ef3a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to Puerto Rico.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.